IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Karan KohliLu YaoTheodore Scott NowickiShihong ZhangRalph Graeme BlackBrett A SchroederErik A FarrarJianhong CaoHeather SloanDawn StiefLee D CranmerMichael J WagnerDouglas S HawkinsVenu G PillarisettyAntoni RibasJean S CampbellRobert H PierceEdward Y KimRobin L JonesStanley R RiddellCassian YeeSeth M PollackPublished in: Journal for immunotherapy of cancer (2022)
ETC targeting NY-ESO-1 with single-agent cyclophosphamide alone conditioning was well tolerated in patients with SS and those with MRCL. IL-15 can induce proliferation and activity in persisting NY-ESO-1-specific T cells even in patients with disease progression following ACT. These results support future work evaluating whether IL-15 could be incorporated into ACT trials post-infusion or at the time of progression.